Table 1 Demographic and clinical characteristics of participants with severe or mild/moderate asthma and control subjects
From: PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma
Mild/moderate asthma (n = 12) | Severe asthma (n = 10) | Healthy control (n = 12) | |
|---|---|---|---|
Sex (male vs. female) | 5 vs. 7 | 4 vs. 6 | 6 vs. 6 |
Age (years) | 45.0 ± 13.9 | 51.8 ± 12.0 | 48.2 ± 12.5 |
History (years) | 15.3 ± 10.9 | 11.9 ± 12.4 | ND |
Allergic rhinitis (n, %) | 8 (66.7%) | 6 (60.0%) | 0 (0%) |
FEV1% pre (mean ± SD) | 75.2 ± 12.7 | 63.2 ± 11.3* | 101 ± 15.5 |
FEV1/FVC (mean ± SD) | 83.7 ± 16.8 | 73.5 ± 18.5* | 97.9 ± 17.2 |
Bronchodilator responsiveness positive (n, %) | 12 (%) | 10 (%) | ND |
FeNO (ppb) (mean ± SD) | 38.9 ± 24.9 | 75.6 ± 21.5* | 19.2 ± 5.7 |
Eosinophils (× 109/l) (mean ± SD) | 0.27 ± 0.25 | 0.35 ± 0.18 | ND |
IgE (IU/ml) (mean ± SD) | 263.9 ± 400.6 | 303.7 ± 261.2 | ND |
ACQ (mean ± SD) | 5.7 ± 1.5 | 11.9 ± 2.9* | ND |
ACT (mean ± SD) | 22.9 ± 6.8 | 16.8 ± 5.1* | ND |
≥ 1 Acute exacerbation during the previous year (n, %) | 2 (16.7%) | 6 (60.0%) | ND |